THE BONNIE J. ADDARIO Lung Cancer Foundation and the Van Auken Private Foundation announced the recipients of the second annual ALCF-VAPF Young Innovators Team Award. The two organizations awarded $500,000 to a team of researchers exploring the causes of chemotherapy resistant small-cell lung cancer and identifying new inhibitors. The winning proposal, by David MacPherson, of...
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
